Several immune-related pathways were significantly down-regulated in KRAS-mutant CRC compared to KRAS wild-type CRC, namely, T1 and T2 cell differentiation, T cell receptor signaling, and nuclear factor kappa-B (NF-κB) signaling pathways. This evidence concerns the gene KRAS and colorectal carcinoma.